Acute Methylenedioxypyrovalerone Toxicity

详细信息    查看全文

• 作者：Blake A. Froberg ; Michael Levine ; Michael C. Beuhler…
• 关键词：Toxicology ; Poisons ; Drug effects ; Central nervous system stimulants ; Street drugs ; Designer drugs
• 刊名：Journal of Medical Toxicology
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：11
• 期：2
• 页码：185-194
• 全文大小：188 KB
• 参考文献：1.Nencini P, Ahmed AM. Khat consumption: a pharmacological review. Drug Alcohol Depend. 1989;23(1):19-9.PubMed View Article
  2.Westphal F, Junge T, Rosner P, Sonnichsen F, Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with alphapyrrolidinophenone structure. Forensic Sci Int. 2009;190(1-):1-.PubMed View Article
  3.Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of second-generation ‘legal highs-in the UK: initial findings. Drug Test Anal. 2010;2(8):377-2.PubMed View Article
  4.Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103(11):875-.PubMed View Article
  5.Ojanpera IA, Heikman PK, Rasanen IJ. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography–mass spectrometry. Ther Drug Monit. 2011;33(2):257-3.PubMed
  6.Emerson TS, Cisek JE. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med. 1993;22(12):1897-03.PubMed View Article
  7.Bronstein AC, Spyker DA, Cantilena Jr LR, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers-National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila). 2011;49(10):910-1.View Article
  8.DAWN. “Bath salts-were involved in over 20,000 drug-related emergency department visits in 20112013 Sept. 17, 2013.
  9.Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts-and “legal highs-(synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49(6):499-05.View Article
  10.Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology. 2013;71:130-0.PubMed Central PubMed View Article
  11.Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol. 1990;30(6):825-.PubMed Central PubMed View Article
  12.Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes. 2013;6:220.PubMed Central PubMed View Article
  13.Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocainelike actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts-products. Neuropsychopharmacology. 2013;38(4):552-2.PubMed Central PubMed View Article
  14.Emergency department visits after use of a drug sold as “bath salts”—Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(19):624-.
  15.Kesha K, Boggs CL, Ripple MG, et al. Methylenedioxypyrovalerone (“bath salts-, related death: case report and review of the literature. J Forensic Sci. 2013;58(6):1654-.PubMed View Article
  16.Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol. 2012;8(3):310-.PubMed Central PubMed View Article
  17.Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts-containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60(1):103-.PubMed View Article
  18.Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts-containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8(1):69-5.PubMed Central PubMed View Article
  19.Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med. 2012;60(1):100-.PubMed View Article
  20.Levine M, Levitan R, Skolnik A. Compartment syndrome after “bath salts-use: a case series. Ann Emerg Med. 2013;61(4):480-.PubMed View Article
  21.Adamowicz P, Gil D, Skulska A, Tokarczyk B. Analysis of MDPV in blood—determination and interpretation. J Anal Toxicol. 2013;37(5):308-2.PubMed View Article
  22.Wright TH, Cline-Parhamovich K, Lajoie D, Parsons L, Dunn M, Ferslew KE. Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci. 2013;58(6):1558-2.PubMed View Article
  23.Wyman JF, Lavins ES, Engelhart D, et al. Postmortem tissue distribution of MDPV following lethal intoxication by “bath salts- J Anal Toxicol. 2013;37(3):182-.PubMed View Article
  24.Warrick BJ, Hill M, Hekman K, et al. A 9-state analysis of designer stimulant, “bath salt- hospital visits reported to poison control centers. Ann Emerg Med. 2013;62(3):244-1.PubMed View Article
  25.Wax PM, Kleinschmidt KC, Brent J. The Toxicology Investigators Consortium (ToxIC) Re
• 作者单位：Blake A. Froberg (1) (12)
  Michael Levine (2) (3)
  Michael C. Beuhler (4)
  Bryan S. Judge (5)
  Philip W. Moore (6)
  Kristin M. Engebretsen (7)
  Nathanael J. Mckeown (8)
  Christopher D. Rosenbaum (9)
  Amy C. Young (10)
  Daniel E. Rusyniak (11)
  On behalf of the ACMT Toxicology Investigators Consortium (ToxIC)
  
  1. Departments of Pediatrics and Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
  12. Pediatrics and Emergency Medicine, 705 Riley Hospital Drive, Indianapolis, IN, 46202, USA
  2. Department of Medical Toxicology, Banner Good Samaritan Medical Center, Phoenix, AZ, USA
  3. Department of Emergency Medicine, University of Southern California, Los Angeles, CA, USA
  4. Department of Emergency Medicine, Carolinas Medical Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  5. Department of Emergency Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA
  6. Department of Medicine, PinnacleHealth, Harrisburg, PA, USA
  7. Department of Emergency Medicine, Regions Hospital, St. Paul, MN, USA
  8. Oregon Poison Center and Portland VA Medical Center, Portland, OR, USA
  9. Department of Emergency Medicine, Tufts University School of Medicine, Boston, MA, USA
  10. Department of Emergency Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
  11. Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
  
• 刊物主题：Pharmacology/Toxicology; Biomedicine general;
• 出版者：Springer US
• ISSN：1937-6995

文摘

The objective of this study was to characterize the acute clinical effects, laboratory findings, complications, and disposition of patients presenting to the hospital after abusing synthetic cathinone. We conducted a retrospective multicenter case series of patients with synthetic cathinone abuse by searching for the terms bath salts, MDPV, methylenedioxypyrovalerone, mephedrone, methcathinone, methylone, methedrone, and cathinone within the “agent-field of a national clinical toxicology database (ToxIC). The medical records of these patients were obtained and abstracted by investigators at each study site. Patients with confirmatory testing that identified a synthetic cathinone in either blood or urine were included in the series. Patients who had either an undetectable synthetic cathinone test or no confirmatory testing were excluded. A data abstraction sheet was used to obtain information on each patient. We entered data into an Excel spreadsheet and calculated descriptive statistics. We identified 23 patients with confirmed synthetic cathinone exposure—all were positive for methylenedioxyprovalerone (MDPV). Eighty-three percent were male and 74?% had recreational intent. The most common reported clinical effects were tachycardia (74?%), agitation (65?%), and sympathomimetic syndrome (65?%). Acidosis was the most common laboratory abnormality (43?%). Seventy-eight percent of patients were treated with benzodiazepines and 30?% were intubated. Ninety-six percent of patients were hospitalized and 87?% were admitted to the ICU. The majority (61?%) of patients was discharged home but 30?% required inpatient psychiatric care. There was one death in our series. The majority of patients presenting to the hospital after abusing MDPV have severe sympathomimetic findings requiring hospitalization. A number of these patients require inpatient psychiatric care after their acute presentation.